Incyte Genomics Inc (INCY) Financials
Key financial figures for Incyte Genomics Inc (Q3 2026).
Incyte Q3 2026 revenue rose 14% to $1.56B, but a one-time $1.23B Vega IPR&D charge produced a GAAP net loss of $784.8M ($3.86 per share) and the company raised 2026 net sales guidance. Total revenue was $1.56B (+14% YoY) and total net sales $1.32B (+14%); Jakafi net sales $827M (+4%, paid demand +12%), Opzelura $255M (+36%), hematology and oncology $235M (+38%). GAAP net loss of $784.8M, or $3.86 per diluted share, versus net income of $424.2M ($2.11) a year earlier, driven by a one-time $1.23B IPR&D expense for the Vega Therapeutics acquisition (closed July 2026, $1.25B in cash plus up to $750M in sales milestones). On the outlook: FY2026 net sales raised: total net sales $5,210-$5,300 million (previously $5,130-$5,260 million); Opzelura $1,100-$1,120 million (previously $1,050-$1,100 million, includes a one-time $246 million CMS benefit); hematology and oncology $890-$910 million (previously $860-$890 million). Jakafi net sales ($3,220-$3,270 million) and GAAP and non-GAAP R&D and SG&A operating expense guidance unchanged; operating expense guidance includes the $1.23 billion Vega IPR&D expense. Figures are for Q3 2026, as Incyte Corporation reported them.
- Revenue
- $1.6B
- Net Income
- -$785M
- EPS
- $-3.86
- Total Assets
- $7.3B
- Operating Cash Flow
- -$675M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $1.6B | -$785M | -$3.86 | -45.49% | -$691M |
| Q2 FY2026 | $1.7B | $586M | $2.81 | 41.69% | $495M |
| Q1 FY2026 | $1.3B | $303M | $1.47 | 23.66% | $359M |
| Q4 FY2025 | $1.5B | $299M | $1.46 | 25.48% | $521M |
| Q3 FY2025 | $1.4B | $424M | $2.11 | 31.57% | $545M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $5.1B | $1.3B | $6.41 | 26.12% | $1.4B |
| FY2024 | $4.2B | $33M | $0.15 | 2.39% | $249M |
| FY2023 | $3.7B | $598M | $2.65 | 17.73% | $464M |
Frequently asked questions
What was Incyte Corporation's revenue last quarter?
Incyte Corporation reported revenue of $1.56 billion for Q3 FY2026, up 14.0% from the same period a year earlier.
Is Incyte Corporation profitable?
Not in its most recent reported period. Incyte Corporation reported a net loss of $784.8 million for Q3 FY2026, a net margin of -50.4% on revenue.
How has Incyte Corporation's margin trended?
Operating margin was -45.49% in Q3 FY2026, compared with 31.57% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Incyte Corporation generate?
Incyte Corporation generated free cash flow of -$691.0 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Incyte Genomics Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.